Nebenwirkungen · Brinavess
BRINAVESS 20 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-123178 · Präparat HOS-095653
Bradycardia Bradycardia was observed predominantly at the time of conversion to sinus rhythm. With a significantly higher conversion rate in patients treated with vernakalant, the incidence of bradycardia events was higher within the first 2 hours in vernakalant treated patients than in placebo-treated patients (1.6 % versus 0 %, respectively). Of the patients who did not convert to sinus rhythm, the incidence of bradycardia events in the first 2 hours post-dose was similar in placebo and vernakalant treated groups (4.0% and 3.8%, respectively). In general, bradycardia responded well to discontinuation of treatment and/or administration of atropine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-07T12:45:00Z · SHA-256 051045e04093fc1285e5944538bcef986071caea205fe960937fd6a5f38d9a56 · Passage 72ddd60a349d511e5cc618e61a08f631ab35073e8f81963126a9105af8feae0c · Zeichen 3443–4100 im Abschnitt